Ann: CEO Presentation to Bioshares Conference, page-34

If my take on it is correct the VenusIII results reflect those expected from the placebo (SC).
If that is incorrect disregard below!!
VenusIII (n=49) .......................... VF00102 (n=113)
week 12 ......... 41% fully healed ............................. ~50% fully healed

week 4......... 25% wound reduction ....................... 50%wound reduction
week 10........ 50% wound reduction ....................... 68% wound reduction
week 12 ...... 55% wound reduction ........................ 70% wound reduction
(Italics means measured from published curve Bioshares presentation)

So the Venus III results, or very similar, would be expected to be embedded in the VF00102 interim results.

Looking at week 12.......taking account of the fully healed to get stated average wound reduction values, the average wound reduction of those not fully healed would be 24% VIII and 40% VF.

Looking quite nice to me so far.